Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

Forget AI Stocks: This Potentially Disruptive Biotech Could Soar By 181%, According to Wall Street ↗

Today 10:20 EDT

This stock could make you a fortune in the next two years, or lose you a whole lot of money.

As of February 27, 2026, the narrative surrounding Novo Nordisk (NYSE: NVO) has undergone a dramatic transformation. For the better part of three years, the Danish pharmaceutical giant was the...

Topics Artificial Intelligence

The Valuation Reset: A Deep-Dive into Novo Nordisk (NVO) in 2026

February 27, 2026

Via Finterra

Topics Economy Intellectual Property

Viking Therapeutics: The High-Stakes Weight Loss Contender ↗

February 26, 2026

Via MarketBeat

Eli Lilly Just Took 2 Major Steps Forward in the Billion-Dollar Obesity Drug Market. Here's What You Need to Know. ↗

February 25, 2026

Eli Lilly has seen revenue and earnings soar in recent years.

Got $5,000? Viking Therapeutics Might Be a Weight‑Loss Drug Moon Shot in the Making. ↗

February 23, 2026

Is this the best way to cash in on the weight-loss gold rush?

Novo Nordisk Shares Tumble 15.1% After CagriSema Fails to Topple Eli Lilly in Head-to-Head Trial

February 23, 2026

The undisputed reign of Novo Nordisk in the weight-loss drug sector faced its most severe challenge to date on February 23, 2026, as the company’s US-traded shares (NYSE: NVO) plummeted 15.1% in a...

A potential competitive threat to Viking's phase 3 weight-loss drug VK2735 was just dealt a major blow.

Why Viking Therapeutics Stock Is Up More Than 9% Today ↗

February 23, 2026

Eli Lilly Surges as Novo Nordisk’s "CagriSema" Stumbles in High-Stakes Obesity Head-to-Head

February 23, 2026

Shares of Eli Lilly (NYSE: LLY) climbed 3.5% on February 23, 2026, as the pharmaceutical giant tightened its grip on the multi-billion-dollar obesity market. The rally was fueled by disappointing...

Novo Nordisk Shares Plunge 13% as Next-Gen Weight Loss Drug CagriSema Fails to Topple Eli Lilly in Landmark Trial

February 23, 2026

COPENHAGEN — Shares of the Danish pharmaceutical giant Novo Nordisk (NYSE: NVO) plummeted more than 13% in premarket trading on Monday, February 23, 2026, following the release of highly anticipated...

Viking stock has plenty of room to run.

Topics Earnings

3 Reasons Viking Therapeutics Stock Could 10X if Its Obesity Pipeline Succeeds ↗

February 23, 2026

These biotech companies have catalysts ahead.

2 Innovative Biotech Stocks That May Climb 58% and 200%, According to Wall Street ↗

February 19, 2026

Never say never. There's certainly a mathematical path to that level, if the company navigates it correctly.

Is Viking Therapeutics Stock Really Going to $125? ↗

February 19, 2026

The Trillion-Dollar Pharmaceutical Giant: Eli Lilly Makes History as Weight-Loss Revolution Drives Unprecedented Growth

February 17, 2026

In a historic moment for the global healthcare industry, Eli Lilly and Company (NYSE:LLY) has officially cemented its position as the world’s first pharmaceutical company to surpass a $1 trillion...

Viking should have plenty of news to share with investors this year.

Topics Earnings Economy

2026 Could Be a Big Year for Viking Therapeutics. Time to Buy? ↗

February 17, 2026

The Great Rotation: Russell 2000 Rockets 18% as Cooling Inflation Sparks Historic Small-Cap Surge

February 13, 2026

The financial landscape shifted violently this week as the long-dormant Russell 2000 index (INDEXRUSSELL:RUT) staged a breathtaking 18% rally, marking its best single-week performance in decades....

In a decisive shift for equity markets, the small-cap heavy Russell 2000 index outperformed its large-cap peers on Friday, February 13, 2026, as investors cheered a cooler-than-expected Consumer Price...

Topics Artificial Intelligence ETFs Economy

Small Caps Roar: Russell 2000 Surges as Cooling Inflation Ignites Rate Cut Hopes

February 13, 2026

VKTX Stock Has Nearly 300% Wall Street Upside — Is Viking’s Oral Obesity Pill The Next Novo Nordisk-Style Breakout? ↗

Topics Bonds ETFs Economy

February 12, 2026

The company ended 2025 with $706 million in cash, which it said is enough to fund ongoing Phase 3 trials and maintenance data readouts.

Viking Therapeutics (NASDAQ:VKTX) stock is soaring on Thursday, extending the momentum it picked up in Wednesday's after‑hours session following the company's fourth‑quarter earnings release.

Viking Therapeutics Stock Soars: What's Driving The Momentum? ↗

February 12, 2026

Via Benzinga

Nasdaq, S&P 500 Futures Rise, Markets Await Jobless Claims: Why NVDA, META, NKTR, NVCR, AMAT, ASTS Are On Traders' Radar Today ↗

February 12, 2026

Viking (VKTX) Q4 2025 Earnings Call Transcript

Topics Stocks

Viking (VKTX) Q4 2025 Earnings Call Transcript ↗

February 11, 2026

Dow, S&P 500 Futures Climb As House Votes To Rescind Trump Tariffs: Why VKTX, NVCR, APP, CRM, QS Are Trending After-Hours ↗

Topics Earnings Intellectual Property

February 11, 2026

The company shared optimistic timelines for advancing the clinical studies of both oral and subcutaneous VK2735 in obesity.

Topics Government Stocks

VKTX Stock Rallies After Hours On Optimism Around Company’s Obesity Pipeline ↗

February 11, 2026

Viking Therapeutics: The Under‑the‑Radar GLP‑1 Contender Growth Hunters Can't Ignore ↗

February 11, 2026

This stock has been known to soar after good news.

Could these two companies be biotech giants in the making?

Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon. ↗

February 10, 2026

Could Eli Lilly Turn Today's GLP‑1 Obesity Boom Into Multi‑Decade, Millionaire‑Maker Gains? ↗

February 10, 2026

The stock has climbed in the triple digits over the past three years.

The most recent gold rush in weight loss drugs isn't done just yet.

3 Things Investors Need to Know About the Healthcare Sector in 2026 ↗

February 07, 2026

Eli Lilly Projects Record $80B-$83B Revenue for 2026 as Metabolic Franchise Decouples from Competition

Topics Economy

February 06, 2026

Eli Lilly and Company (NYSE: LLY) has officially entered the "trillion-dollar club" with a roar, issuing a blockbuster financial guidance for 2026 that projects revenue between $80 billion and $83...

The Great GLP-1 Divergence: Eli Lilly Surges Toward Trillion-Dollar Dominance as Novo Nordisk Falters on U.S. Price Cuts

Topics Earnings Economy

February 05, 2026

In a dramatic week for the pharmaceutical sector, a stark rift has opened between the two undisputed titans of the weight-loss drug market. On February 4, 2026, Eli Lilly (NYSE:LLY) reported a...

This pre-revenue biopharmaceutical stock is a home run swing worth taking.

Topics Earnings Economy

The Smartest Growth Stock to Buy With $30 Right Now ↗

February 03, 2026